GET THE APP

Discovery and translation of epitomics biomarkers: Towards diagno | 29184
Journal of Proteomics & Bioinformatics

Journal of Proteomics & Bioinformatics
Open Access

ISSN: 0974-276X

+44 1223 790975

Discovery and translation of epitomics biomarkers: Towards diagnostics


5th International Conference on Proteomics & Bioinformatics

September 01-03, 2015 Valencia, Spain

Jozsef Lazar

Biosystems International Kft., Hungary

Scientific Tracks Abstracts: J Proteomics Bioinform

Abstract :

Proteome variability is currently addressed via technologies dominated by various forms of mass spectrometry (MS), which almost exclusively address quantitative aspects only. One major caveat of the MS approach is that it misses dynamic changes of qualitative attributes of the proteome. Qualitative changes of the proteome variability among others, involve genetic code dependent variation such as alternative splicing, allelic variants and combinatorial variability of multi-chain proteins, while stochastic variability with a less prominent genetic component include changes in post translational modification, folding variability, degradation regulated extracellular processing and complexing. Qualitative changes of the proteome are the sources of epitome variability. In order to reproducibly test epitome variability, we generated mAb libraries (Quantiplasma 69 and 300, QP69 and QP300) directed against 2-10 independent epitopes of major and medium abundant proteins (approx. 70-100) of the human plasma. For profiling the epitome, we developed biochips running on the Evidence investigator platform of Randox Ltd. UK. Epitome profiles seem to provide high quality disease specific epitope panels even after testing relatively small portion of the epitome. In order to investigate potential diagnostic applications of specific epitome profiles we aimed at analytical validation and testing translatability (to 96 well ELSA format) of the QP69 and QP300 biochip profiles to lower complexity diagnostics candidates. Thus it can be concluded that Quantiplasma biochips are useful for reproducible epitome profiling and for potential application as diagnostics.

Biography :

Jozsef Lazar obtained his MSc degree in Molecular Biology and PhD in Physiology and Neurobiology at the University of Debrecen, Hungary. Before his industrial experience, he was a Post-doctoral visiting fellow in the Laboratory of Cancer Biology and Genetics of NCI, National Institute of Health, USA. He joined Biosystems International in 2009 and became the Head of R&D Laboratory since 2012. Beside his industrial work he also participated in academic activities in the Department of Human Genetics at the University of Debrecen in Hungary.

Email: jozsef.lazar@biosys-intl.com

Top